Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.
作者信息
Yeramaneni Samrat, Doshi Pratik, Sands Kenneth, Cooper Mandelin, Kurbegov Dax, Fromell Gregg
机构信息
Sarah Cannon Research Institute, HCA Healthcare, Nashville, Tennessee.
Clinical Operations Group, HCA Healthcare, Nashville, Tennessee.
出版信息
Gastroenterology. 2021 Feb;160(3):919-921.e3. doi: 10.1053/j.gastro.2020.10.011. Epub 2020 Oct 12.
Abstract
摘要
相似文献
1
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.法莫替丁的使用与30天死亡率无关：一项对来自大型医疗保健系统的7158例2019冠状病毒病住院患者的粗匹配精确研究。
Gastroenterology. 2021 Feb;160(3):919-921.e3. doi: 10.1053/j.gastro.2020.10.011. Epub 2020 Oct 12.
2
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.法莫替丁对 COVID-19 住院患者临床结局的影响。
Am J Gastroenterol. 2020 Oct;115(10):1617-1623. doi: 10.14309/ajg.0000000000000832.
3
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.法莫替丁治疗住院 COVID-19 患者的疗效比较。
Am J Gastroenterol. 2021 Apr;116(4):692-699. doi: 10.14309/ajg.0000000000001153.
4
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.法莫替丁能否降低新冠病毒肺炎患者进展为重症疾病、死亡及插管的风险？一项系统评价与Meta分析
Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.
5
The association between famotidine and in-hospital mortality of patients with COVID-19.法莫替丁与 COVID-19 患者住院死亡率的关联。
J Med Virol. 2022 Mar;94(3):1186-1189. doi: 10.1002/jmv.27375. Epub 2021 Oct 11.
6
Famotidine Against SARS-CoV2: A Hope or Hype?法莫替丁对新型冠状病毒2：希望还是炒作？
Mayo Clin Proc. 2020 Aug;95(8):1797-1799. doi: 10.1016/j.mayocp.2020.05.027. Epub 2020 Jun 6.
7
Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis.法莫替丁对 COVID-19 住院患者的影响：系统评价和荟萃分析。
PLoS One. 2021 Nov 4;16(11):e0259514. doi: 10.1371/journal.pone.0259514. eCollection 2021.
8
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.
9
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.法莫替丁在 2019 年新型冠状病毒疾病中的再利用：系统评价。
Drug Res (Stuttg). 2021 Jul;71(6):295-301. doi: 10.1055/a-1397-6763. Epub 2021 Mar 23.
10
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
引用本文的文献
1
A retrospective analysis of clinical outcomes between hospitalized patients with COVID-19 who received famotidine or pantoprazole.对接受法莫替丁或泮托拉唑治疗的新冠肺炎住院患者临床结局的回顾性分析。
JGH Open. 2023 Jul 10;7(7):464-469. doi: 10.1002/jgh3.12905. eCollection 2023 Jul.
2
Effectiveness of famotidine on the risk of poor prognosis in patients with COVID-19: A nationwide cohort study in Korea.法莫替丁对新型冠状病毒肺炎患者预后不良风险的有效性：韩国一项全国性队列研究
Heliyon. 2023 Jun;9(6):e16171. doi: 10.1016/j.heliyon.2023.e16171. Epub 2023 Jun 1.
3
Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.组胺 2 受体拮抗剂和质子泵抑制剂与 SARS-CoV-2 感染风险降低相关，无论是否存在糖尿病、高血压和血脂异常等合并症：一项倾向评分匹配的全国队列研究。
J Korean Med Sci. 2023 Apr 3;38(13):e99. doi: 10.3346/jkms.2023.38.e99.
4
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.COVID-19 对肝脏的影响以及对慢性肝病、肝胆癌和肝移植患者的治疗影响：EASL 最新立场文件。
J Hepatol. 2022 Oct;77(4):1161-1197. doi: 10.1016/j.jhep.2022.07.008. Epub 2022 Jul 20.
5
Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies.COVID-19 的胃肠道预防：来自观察性研究中不恰当对照导致严重偏倚的实例。
J Clin Epidemiol. 2022 Nov;151:45-52. doi: 10.1016/j.jclinepi.2022.07.009. Epub 2022 Jul 20.
6
Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients.组胺2受体拮抗剂不能改善住院的2019冠状病毒病患者的治疗结果。
Prz Gastroenterol. 2022;17(2):146-151. doi: 10.5114/pg.2021.107799. Epub 2021 Jul 14.
7
Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.COVID-19 临床更新：为急诊和危重症临床医生提供的医学管理建议
Am J Emerg Med. 2022 Jun;56:158-170. doi: 10.1016/j.ajem.2022.03.036. Epub 2022 Mar 26.
8
Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis.法莫替丁对 COVID-19 住院患者的影响：系统评价和荟萃分析。
PLoS One. 2021 Nov 4;16(11):e0259514. doi: 10.1371/journal.pone.0259514. eCollection 2021.
9
A Birds-Eye (Re)View of Acid-Suppression Drugs, COVID-19, and the Highly Variable Literature.酸抑制药物、COVID-19及高度多样化文献的鸟瞰（再审视）
Front Pharmacol. 2021 Aug 11;12:700703. doi: 10.3389/fphar.2021.700703. eCollection 2021.
10
The COVID-19 Menace.新冠疫情的威胁。
Glob Chall. 2021 May 7;5(9):2100004. doi: 10.1002/gch2.202100004. eCollection 2021 Sep.
本文引用的文献
1
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.法莫替丁对 COVID-19 住院患者临床结局的影响。
Am J Gastroenterol. 2020 Oct;115(10):1617-1623. doi: 10.14309/ajg.0000000000000832.
2
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.法莫替丁的使用与住院COVID-19患者临床结局改善相关：一项倾向评分匹配的回顾性队列研究。
Gastroenterology. 2020 Sep;159(3):1129-1131.e3. doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.
3
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
4
Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.通过对已过专利期药物的真实世界再利用来快速实现效益：以 COVID-19 大流行为例。
JMIR Public Health Surveill. 2020 May 13;6(2):e19199. doi: 10.2196/19199.
5
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
Zotero 插件